Wednesday, September 3, 2025

Firefly Expands Data, IP & Reach via Evoke Acquisition

Related stories

Varonis Acquires SlashNext to Counter AI Email Threats

Varonis Systems, Inc., a global leader in data security,...

ENGIE & Prometheus to Build AI-Ready Data Centers in Texas

ENGIE North America (ENGIE) has entered into a strategic...

TestingXperts Launches QXcel, AI-Powered Quality Platform

TestingXperts (Tx), a global leader in digital assurance and...

Ardoq Unveils AI Management Tool to Govern and De-Risk Adoption

Ardoq, a SaaS company redefining Enterprise Architecture, has introduced...

Portnox-SentinelOne Integration Delivers Real-Time Access Control

Portnox, a leading provider of zero trust access control...
spot_imgspot_img

Firefly Neuroscience, Inc., an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to announce its acquisition of Evoke Neuroscience, Inc. (“Evoke”), a medical device company developing and commercializing technologies to aid in the comprehensive assessment of brain health. The transaction marks another important step toward Firefly building a proprietary foundation model of the human brain using its FDA-cleared Brain Network Analytics (“BNA™”) technology.

Also Read: BrainChip Launches Edge AI Box Ecosystem

As a result of the acquisition, Firefly’s assets and business now include:   

  • The largest known proprietary database of >180,000 standardized, EEG/ERP assessment records
  • 27 granted patents
  • >60 current commercial users

These increases in propriety brain scans, patents and commercial sites represent greater than two-fold, three-fold and 10-fold expansions, respectively, as a result of the acquisition.

Source: Globenewswire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img